manilatimes11 小时
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...
Business Wire22 小时
Xencor Reports Third Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...